Question explored with the scientific record
Conversation so far
- 1 Lamictal
- 2 Lamictal and should you taper off it
- 3 Lamictal and if you taper off it can it cause siezures and death for eplipsy
Answered on this page ↓
Lamictal and if you taper off it can it cause siezures and death for eplipsy
Yes. Stopping lamotrigine in someone with epilepsy can bring seizures back, and a bad seizure can kill. That is the real risk, and it is why you taper slowly with a doctor rather than quit.
The records don't include a study of lamotrigine withdrawal in epilepsy. What they do show is that the drug is doing real work: in newly diagnosed epilepsy, lamotrigine held seizure control about as well as carbamazepine and phenytoin over 48 weeks [2], and 75% of 91 patients followed up to 107 weeks stayed seizure free [2]. Take that away and the seizures it was suppressing can return.
The death risk is not the taper itself. It is what an uncontrolled seizure can do. In a 30-year cohort of teenagers with epilepsy, 4 patients died and 3 of those were probable sudden unexpected death in epilepsy (SUDEP), all in people whose seizures were uncontrolled [3]. That is the mechanism that makes abrupt withdrawal dangerous.
One twist worth knowing: lamotrigine can also make seizures worse in certain rare epilepsy syndromes. In 21 children with severe myoclonic epilepsy, 17 got worse on the drug [1], and one child with Lennox-Gastaut developed myoclonic status epilepticus after a dose increase, which resolved when the drug was stopped [4]. So for a few patients, stopping is the safer move, not the riskier one.
| Situation | What the evidence shows |
|---|---|
| Lamotrigine vs older drugs, 48 weeks [2] | No significant difference in seizure recurrence |
| Seizure-free on long-term lamotrigine [2] | 75% of 91 evaluated |
| Deaths in teen epilepsy cohort [3] | 4 total, 3 probable SUDEP, all uncontrolled |
| Worsening on lamotrigine, severe myoclonic epilepsy [1] | 17 of 21 |
My call: taper slowly under medical supervision, never stop abruptly, and treat any returning seizure as urgent. Confidence: moderate that withdrawal raises seizure risk, low on the exact taper schedule, because no study here tested one.
Sources used 4
-
Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
In an open-label series of 21 children and adolescents with severe myoclonic epilepsy of infancy, lamotrigine treatment was followed by global worsening in 17 (80%), no substantial change in 3, and improvement in 1.
DOI: 10.1111/j.1528-1157.1998.tb01413.x -
Overview of Lamotrigine and the New Antiepileptic Drugs: The Challenge
Lamotrigine is effective as monotherapy or adjunctive therapy for pediatric and adult epilepsy, but its use requires balancing efficacy against serious rash risks, especially in children and with valproate or rapid titration.
DOI: 10.1177/0883073897012001111 -
Pharmacological outcomes in teenagers with newly diagnosed epilepsy: A 30‐year cohort study
A 30-year prospective cohort study assessing long-term pharmacological outcomes in 332 teenagers (13–19 at treatment start) with newly diagnosed epilepsy, reporting seizure control, relapse, withdrawal outcomes, tolerability across antiepileptic drugs, and differences between ge…
DOI: 10.1111/epi.15664 -
Myoclonic status epilepticus following high-dosage lamotrigine therapy
This case study describes an 8-year-old girl with Lennox-Gastaut syndrome who developed myoclonic status epilepticus following an increase in lamotrigine dosage, which resolved rapidly upon discontinuation of the drug, suggesting a potential paradoxical effect of lamotrigine in …
DOI: 10.1016/s0387-7604(99)00048-0